NERV vs. BNTC, ORGS, VBIV, HUGE, KALA, NRSN, FLGC, GLTO, TCRT, and TLPH
Should you be buying Minerva Neurosciences stock or one of its competitors? The main competitors of Minerva Neurosciences include Benitec Biopharma (BNTC), Orgenesis (ORGS), VBI Vaccines (VBIV), FSD Pharma (HUGE), KALA BIO (KALA), NeuroSense Therapeutics (NRSN), Flora Growth (FLGC), Galecto (GLTO), Alaunos Therapeutics (TCRT), and Talphera (TLPH). These companies are all part of the "pharmaceutical preparations" industry.
Minerva Neurosciences (NASDAQ:NERV) and Benitec Biopharma (NASDAQ:BNTC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
Minerva Neurosciences received 166 more outperform votes than Benitec Biopharma when rated by MarketBeat users. However, 63.73% of users gave Benitec Biopharma an outperform vote while only 60.98% of users gave Minerva Neurosciences an outperform vote.
Minerva Neurosciences presently has a consensus price target of $11.00, suggesting a potential upside of 356.43%. Benitec Biopharma has a consensus price target of $16.00, suggesting a potential upside of 114.77%. Given Minerva Neurosciences' higher possible upside, equities research analysts plainly believe Minerva Neurosciences is more favorable than Benitec Biopharma.
Benitec Biopharma has higher revenue and earnings than Minerva Neurosciences.
Minerva Neurosciences' return on equity of 0.00% beat Benitec Biopharma's return on equity.
34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 52.2% of Benitec Biopharma shares are held by institutional investors. 6.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 4.3% of Benitec Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Minerva Neurosciences has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.03, indicating that its stock price is 3% more volatile than the S&P 500.
In the previous week, Minerva Neurosciences had 1 more articles in the media than Benitec Biopharma. MarketBeat recorded 3 mentions for Minerva Neurosciences and 2 mentions for Benitec Biopharma. Minerva Neurosciences' average media sentiment score of 0.25 beat Benitec Biopharma's score of 0.00 indicating that Minerva Neurosciences is being referred to more favorably in the media.
Summary
Minerva Neurosciences and Benitec Biopharma tied by winning 7 of the 14 factors compared between the two stocks.
Get Minerva Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for NERV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NERV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Minerva Neurosciences Competitors List
Related Companies and Tools
